Experimental treatments
for Myelofibrosis

Imetelstat is an infusion therapy that’s being developed by Geron for myelofibrosis when used alone or in combination with the approved JAK inhibitor Jakafi (ruxolitinib).

Navtemadlin is an oral therapy that’s being developed by Kartos Therapeutics for the treatment of myelofibrosis in people who did not respond well enough to JAK inhibitors. It’s being tested when used as a standalone therapy or as a part of a combination therapy with the approved JAK inhibitor Jakafi (ruxolitinib).

Pelabresib is an oral therapy that’s being developed by Novartis for the treatment of myelofibrosis when used in combination with the approved JAK inhibitor Jakafi (ruxolitinib).

Selinexor is an oral therapy that’s being developed by Karyopharm Therapeutics for the treatment of myelofibrosis when used alone or in combination with the approved JAK inhibitor Jakafi (ruxolitinib).